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Abstract
Background: Lanthionine synthetase component C-like protein 2 (LANCL2) is a member of the eukaryotic lanthionine
synthetase component C-Like protein family involved in signal transduction and insulin sensitization. Recently, LANCL2 is a
target for the binding and signaling of abscisic acid (ABA), a plant hormone with anti-diabetic and anti-inflammatory effects.
Methodology/Principal Findings: The goal of this study was to determine the role of LANCL2 as a potential therapeutic
target for developing novel drugs and nutraceuticals against inflammatory diseases. Previously, we performed homology
modeling to construct a three-dimensional structure of LANCL2 using the crystal structure of lanthionine synthetase
component C-like protein 1 (LANCL1) as a template. Using this model, structure-based virtual screening was performed
using compounds from NCI (National Cancer Institute) Diversity Set II, ChemBridge, ZINC natural products, and FDA-
approved drugs databases. Several potential ligands were identified using molecular docking. In order to validate the anti-
inflammatory efficacy of the top ranked compound (NSC61610) in the NCI Diversity Set II, a series of in vitro and pre-clinical
efficacy studies were performed using a mouse model of dextran sodium sulfate (DSS)-induced colitis. Our findings showed
that the lead compound, NSC61610, activated peroxisome proliferator-activated receptor gamma in a LANCL2- and
adenylate cyclase/cAMP dependent manner in vitro and ameliorated experimental colitis by down-modulating colonic
inflammatory gene expression and favoring regulatory T cell responses.
Conclusions/Significance: LANCL2 is a novel therapeutic target for inflammatory diseases. High-throughput, structure-
based virtual screening is an effective computational-based drug design method for discovering anti-inflammatory LANCL2-
based drug candidates.
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Introduction
Prokaryotic LanC is a part of a multimeric membrane-
associated lanthionine synthetase complex involved in the
modification and transport of peptides. LanC itself is a zinc-
containing enzyme that acts in concert with specific dehydratases
to facilitate intramolecular conjugation of cysteine to serine or
threonine residues, yielding macrocyclic thioether analogs of
cysteine known as lanthionines. These products display potent
antimicrobial activity, and are also known as lantibiotics [1]. The
first member of the eukaryotic lanthionine synthetase component
C-like (LANCL) protein family, LANCL1, was isolated from
human erythrocyte membranes [2]. A related protein, LANCL2,
was subsequently identified in human brain and testis [3].
LANCL1 and 2 have similar expression patterns, with strong
expression in brain and testis, and weak but ubiquitous expression
in other tissues [2,3]. LANCL2 is most highly expressed in testis,
and its exogenous introduction has been shown to cause increased
cellular sensitivity to the anticancer drug, adriamycin, by
suppressing the expression of MultiDrug-Resistance 1 and its
cognate protein, P-glycoprotein [4]. On the other hand,
overexpressed LANCL2 interacted with the actin cytoskeleton,
implying that LANCL2 may also have a role in cytoskeletal
reorganization and cellular movement [5].
Sturla and colleagues provided in vitro results suggesting that
LANCL2 is required for abscisic acid (ABA) binding to the
membrane of human granulocytes and for transduction of the
ABA signal into cell-specific functional responses in granulocytes
[6]. ABA is an isoprenoid phytohormone that plays important
roles in plant responses to environmental stresses and host
responses [7]. In addition, ABA has received recent attention
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activating and anti-inflammatory properties, which make it a
target for development of potent anti-inflammatory and insulin-
sensitizing therapeutics [7]. We demonstrated that PPAR c is
required for ABA to induce its full spectrum of effects, but ABA
does not bind directly to the ligand-binding domain (LBD) of
PPAR c [8]. The mechanism of activation of PPAR c by ABA is
not completely understood, but there is evidence supporting the
observation that ABA-mediated PPAR c activation requires
expression of LANCL2 in immune cells [8]. Indeed, we
demonstrated that ABA binds to LANCL2 in silico [8]. Moreover,
by using molecular modeling approaches, we elucidated the
location of the potential LBD of LANCL2 for ABA. Recently, a
series of in vitro binding studies on human LANCL2 recombinant
protein confirmed direct binding of ABA to LANCL2, including
saturation binding, scintillation proximity assays, dot blot
experiments, and affinity chromatography [9]. Identification of
ABA binding to LANCL2 paves the way for the discovery and
development novel anti-inflammatory drugs that target LANCL2.
Based on previous findings, we proposed that LANCL2 might be a
putative novel target for the discovery and development of orally
active, broad-based drugs against inflammatory, infectious and
chronic metabolic diseases [10].
The predominant technique employed in the identification of
new drugs is the physical large scale, high-throughput screening of
thematic compound libraries against a biological target, which is
very costly and yields mixed results. Recent successes in predicting
new ligands and their receptor-bound structures make use of
structure-based virtual screening (SBVS), which is a more cost-
effective approach in drug and nutraceutical discovery. The basic
procedure of SBVS is to sample binding geometry for compounds
from large libraries into the structure of receptor targets by using
molecular modeling approaches. Each compound is sampled in
thousands to millions of possible poses and scored on the basis of
its complementarity to the receptor. Of the hundreds of thousands
of molecules in the library, tens of top-scoring predicted ligands
are subsequently tested for activity in experimental assays [11].
One of the main requirements for SBVS is availability of the three-
dimensional structure of a validated protein target [12]. In some
cases, when the crystal structure of the receptor target is unknown,
computer-modeled structures have been verified to suffice for
successful virtual screening [13,14,15,16]. In a previous study from
our group, homology modeling of human LANCL2 was
performed using the crystal structure of human LANCL1 as a
template [17] and the model quality was assessed [10].
We performed LANCL2-based virtual screening using the
structure of LANCL2 obtained through homology modeling to
discover new LANCL2 agonists. Thousands of compounds from
NCI Diversity Set II, ChemBridge, ZINC natural products and
U.S. Food and Drug Administration (FDA)-approved drug
databases were docked into the LANCL2 model and ranked by
the calculated affinity. The effect of the top ranked compound in
the NCI Diversity Set II, the benzimidazophenyl compound
denoted NSC61610, on the activity of PPAR c was tested in vitro
using a dual luciferase reporter activity assay. Its in vivo efficacy and
cell-specific PPAR c dependency were then examined using a
mouse model of experimental IBD.
Materials and Methods
Expression of LANCL2 in Mouse Tissues
Proteins were extracted from different mouse tissue, including
thymus, lung, spleen, stomach, ileum, colon, Peyer’s patches (PP),
mesenteric lymph node (MLN), gastric lymph node (GLN), blood,
white adipose tissue (WAT), and bone marrow (BM) as previously
described [8]. The protein extracts were analyzed using a 10%
SDS-PAGE gel in a Bio-Rad mini-gel box running condition
(75 V63 hrs). Afterward, proteins were electrotransferred to
nitrocellulose by standard methods along with the Precision Plus
Kaleidoscope Standard (BIO-RAD). Filters were blocked by 5%
BSA in TBS-Tween for 1 hour, followed by incubation with rabbit
anti-LANCL2 primary antibody (SIGMA-ALDRICH) in TBS-
Tween for 6 hours at room temperature. Goat anti-rabbit
horseradish peroxidase-conjugated secondary antibody (Santa
Cruz Biotechnology) was used at a dilution of 1:2000 in TBS-
Tween, and protein bands were detected with Immun-StarTM
chemiluminescent substrate (BIO-RAD). Re-probing western blot
was applied by incubating nitrocellulose in stripping buffer
(Thermo scientific) for 15 minutes.
Compound Database Management and Ligand Structure
The structure files of compounds were obtained from the ZINC
database in mol2 format [18], and the individual mol2 files were
converted into pdbqt files using the python script prepare_li-
gand4.py available in the Autodock Tools package [19]. The NCI
diversity set II is a reduced set of 1,364 compounds selected from
the almost 140,000 compounds available for distribution from the
DTP (Developmental Therapeutics Program) repository. The
selection process is outlined in more detail at the NCI DTP
website (http://www.dtp.nci.nih.gov/branches/dscb/div2_explan
ation.html). The ChemBridge Corporation maintains a stock of
more than 800,000 drug-like and lead-like screening compounds.
Structures for these compounds are available for download from
the ZINC database (http://zinc.docking.org/vendor0/chbr/
index.html). The ZINC natural products database has a structure
collection of 89,425 natural products available for download from
the ZINC database (http://zinc.docking.org/vendor0/npd/index.
html). The FDA-approved drugs database includes 3,180 FDA-
approved drug structures, which also are available for download
from the ZINC database (http://zinc.docking.org/vendor0/fda/
index.html).
Virtual Screening
The docking of compounds available in the NCI Diversity Set
II, ChemBridge, ZINC natural products and FDA-approved drugs
databases into the LANCL2 computational model was performed
with AutoDock Vina (version 1.0) [20]. AutoDockTools, the
graphical front-end for AutoDock and AutoGrid, was used to
define the search space, including grid box center and x,y,z-
dimensions [19]. A variety of stochastic global optimization
approaches were used in AutoDock Vina, including genetic
algorithms, particle swarm optimization, simulated annealing and
others. Five bound conformations were generated by AutoDock
Vina for each compound. The docking was applied to the whole
protein target, with a grid covering the whole surface of the
protein. To search the entire surface of LANCL2, grid maps were
set with the maximum spacing between grid points. The grid was a
rectangular cuboid (70 A ˚670 A ˚660 A ˚) with grid points separated
by 1.000 A ˚ and centered at the middle of the protein. This grid
was big enough to cover the entire surface of LANCL2.
Analyzing the Virtual Screening Results
The search for the best way to fit each compound into LANCL2
using AutoDock Vina resulted in docking log files that contained
records of docking, including binding energy of each predicted
binding mode for all the compounds. Binding energies represent
the sum of the total intermolecular energy, total internal energy
and torsional free energy minus the energy of the unbound system.
Discovery of Anti-Inflammatory Drugs Target LANCL2
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energy value. All predicted binding poses were placed into one
multimodel PDBQT file.
PPAR c Reporter Activity Assays on Raw Macrophages
To determine PPAR c activity, pCMX.PPAR c expression
plasmid and a pTK.PPRE3x luciferase reporter plasmid driven by
the peroxisome proliferator responsive element-containing Acyl-
CoA oxidase promoter were purified using maxi kit from Qiagen
(Valencia, CA). RAW 264.7 macrophages were cultured with
DMEM (Mediatech, Manassas, VA) containing 10% fetal bovine
serum (FBS) and grown until 60–70% confluence. Cells were
cotransfected in two 25 cm2 flasks with 1.5 mg plasmid of DNA
and 0.15 mg of pRL reporter control with or without 100 pmol
LANCL2 siRNA using Lipofectamine 2000 transfection reagent
(Invitrogen) according to the manufacturer’s protocol. After 24 h,
transfected cells were seeded into white, opaque 96-well plates (BD
Biosciences) at a concentration of 25,000 cells/well. Transfected
cells were then treated in replicates with rosiglitazone (Ros 1 mM;
Cayman Chemical, Ann Arbor, MI), NSC61610 (2.5 mM) with
and without 2959-dideoxyadenosine (10 mM; Sigma) or vehicle
(DMSO) and placed in a 37uC incubator with 5% CO2. After
20 h, cells were harvested in reporter lysis reagent. Luciferase
activity, normalized to pRL activity in the cell extracts, was
determined by using the Dual-Luciferase II reporter assay system
(Promega, Madison, WI) using a Modulus 96-well luminometer
(Turner Biosystems, Sunnyvale, CA). All values were normalized
to control wells to calculate relative luciferase activity.
Ethics Statement
All experimental procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) of Virginia Tech and
met or exceeded requirements of the Public Health Service/
National Institutes of Health and the Animal Welfare Act. The
IACUC approval ID for the study was 11-057-VBI.
Animal Procedures to Test the Anti-inflammatory Efficacy
of Lead Compound NSC61610 in IBD
Eight week old C57BL/6J mice were housed at the animal
facilities at Virginia Tech in a room maintained at 75uF, with a
12:12 hr light-dark cycle starting from 6:00 AM. Mice were
randomly assigned into four groups: a control group including 8
mice and the other three NSC61610 treatment groups containing
10 mice each. The three treatment groups received 0.5, 10 or
20 mg NSC61610/kg body weight by orogastric gavage for 7
days. All the mice were challenged with 2.5% DSS, 36,000–44,000
molecular weight (ICN Biomedicals, Aurora, OH) in the drinking
water for 7 days. Mice were weighed on a daily basis and
examined for clinical signs of disease associated with colitis (i.e.,
perianal soiling, rectal bleeding, diarrhea, and piloerection). For
the DSS challenge, the disease activity indices (DAIs) and rectal
bleeding scores were calculated using a modification of a
previously published compounded clinical score [21]. Briefly,
DAI consisted of a scoring for diarrhea and lethargy (0–3), whereas
rectal bleeding consisted of a visual observation of blood in feces
and the perianal area (0–4). On day 7 of the challenge, mice in the
DSS study were euthanized.by CO2 narcosis followed by
secondary thoracotomy and blood was drawn from the heart.
Colon, spleen, and MLN were scored based on size and
macroscopic inflammatory lesions (0–3), excised, and single-cell
suspensions were prepared for flow cytometric analyses.
Histopathology
Colonic sections were fixed in 10% buffered neutral formalin,
later embedded in paraffin, and then sectioned (5 mm) and stained
with H&E stain for histologic examination. Colons were blindly
graded with a compounded histologic score including the extent of
(1) leukocyte infiltration, (2) mucosal thickening, and (3) epithelial
cell erosion. The sections were graded with a score of 0–4 for each
of the previous categories and data were analyzed as a normalized
compounded score as previously described [21].
Quantitative Real-time RT-PCR
Total RNA was isolated from colons using the RNA isolation
Minikit (Qiagen) according to the manufacturer’s instructions.
Total RNA (1 mg) was used to generate complementary DNA
(cDNA) template using the iScript cDNA Synthesis Kit (Bio-Rad,
Hercules, CA). The total reaction volume was 20 mL with the
reaction incubated as follows in an MJ MiniCycler: 5 min at 25uC,
30 min at 52uC, 5 min at 85uC, and hold at 4uC. PCR was
performed on the cDNA using Taq DNA polymerase (Invitrogen,
Carlsbad, CA) and using previously described conditions. Each
gene amplicon was purified with the MiniElute PCR Purification
Kit (Qiagen) and quantitated on an agarose gel by using a DNA
mass ladder (Promega). These purified amplicons were used to
optimize quantitative real-time RT-PCR conditions and to
generate standard curves. Primer concentrations and annealing
temperatures were optimized for the iCycler iQ system (Bio-Rad)
for each set of primers using the system’s gradient protocol. PCR
efficiencies were maintained between 92 and 105% and
correlation coefficients above 0.98 for each primer set during
optimization and also during the real-time PCR of sample DNA.
cDNA concentrations for genes of interest were examined by
RT-PCR using an iCycler IQ System and the iQ SYBR green
supermix (Bio-Rad). A standard curve was generated for each gene
using 10-fold dilutions of purified amplicons starting at 5 pg of
cDNA and used later to calculate the starting amount of target
cDNA in the unknown samples. SYBR green I is a general double-
stranded DNA intercalating dye and may therefore detect non-
specific products and primer/dimers in addition to the amplicon of
interest. In order to determine the number of products synthesized
during the real-time PCR, a melting curve analysis was performed
on each product. RT- PCR was used to measure the starting
amount of nucleic acid of each unknown sample of cDNA on the
same 96-well plate. Results are presented as starting quantity of
target cDNA (picograms) per microgram of total RNA as
previously described [21]. Primer sequences and Genebank
accession numbers are outlined in Table S1.
Immunophenotyping of tissues of mice with IBD
Colonic lamina proprial lymphocytes (LPL) were isolated from
digested colons. Spleens and MLNs were excised and single cell
suspensions were prepared. Splenocytes were freed of red blood
cells with erythrocyte lysis buffer, and spleen and MLN were
resuspended in PBS and enumerated by using a Coulter Counter
(Beckman Coulter, Fullerton, CA). LPL, spleen and MLN-derived
cells (2610
5 cells/well) or whole blood (10 mL/well) were seeded
onto 96-well plates, centrifuged at 4uC at 3000 rpm for 4 min, and
washed with PBS containing 5% serum and 0.09% sodium azide
(FACS buffer). To assess differential monocyte/macrophage
infiltration, the cells were then incubated in the dark at 4uC for
20 min in FcBlock (20 mg/ml, BD Pharmingen) for macrophage
assessment, and then for an additional 20 min with fluorochrome-
conjugated primary antibodies anti-F4/80-PE-Cy5 (0.2 mg/mL,
ebioscience) and anti-CD11b-Alexa Fluor 700 (0.2 mg/mL, BD
Pharmingen). For lymphocyte subset assessment, cells were
Discovery of Anti-Inflammatory Drugs Target LANCL2
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BD Pharmingen), anti-CD4-PE-Cy7 (0.2 mg/mL, BD Pharmin-
gen), anti-CD8-PerCp-Cy5.5 (0.2 mg/mL, eBioscience), anti-
CD3-PE-Cy5 (0.2 mg/mL, ebioscience), anti-FoxP3-APC
(0.2 mg/mL, eBioscience), and anti-IL10-FITC (0.5 mg/mL,
BD Pharmingen). Flow results were computed with a BD LSR
II flow cytometer and data analyses were performed with FACS
Diva software (BD).
Characterization of the Immunoregulatory Mechanisms
of NSC61610 in Mice with Experimental IBD
PPAR c fl/fl Cre- (n=20), tissue-specific PPAR c fl/fl CD4-
Cre+ (T cell-deficient) PPAR c null mice (n=20) and tissue-
specific PPAR c fl/fl Lysozyme M-Cre+ (myeloid-deficient) PPAR
c null mice (n=20) in a C57BL/6J background were generated by
using the Cre-lox recombination system as previously described
[21]. In each group, 20 mice were randomly divided into two
groups: a control group including 10 mice and a NSC61610
treatment group containing 10 mice. The three treatment groups
received 20 mg/kg NSC61610 by orogastric gavage for 6 days.
We selected 20 mg/kg for subsequent testing in this study because
this dose had shown the greatest anti-inflammatory activity in the
dose-response study (described above). All the mice (n=60) were
challenged with drinking water containing 2.5% DSS, 36,000–
44,000 molecular weight (ICN Biomedicals, Aurora, OH) for 6
days. Mice were weighed on a daily basis and examined for clinical
signs of disease associated with colitis. For the DSS challenge, the
disease activity indices and rectal bleeding scores were calculated
using a modification of a previously published compounded
clinical score [21]. Mice in the DSS study were euthanized on day
6 of the DSS challenge. On day 6, colon, spleen, and MLN were
scored based on size and macroscopic inflammatory lesions (0–3),
excised, and then crushed to produce single-cell suspensions for
flow cytometry.
Statistics
Data were analyzed as a completely randomized design. To
determine the statistical significance of the model, analysis of
variance (ANOVA) was performed using the general linear model
procedure of Statistical Analysis Software (SAS), and probability
value (P),0.05 was considered to be significant. When the model
Figure 1. Lanthionine synthetase C-like 2 (LANCL2) and NSC61610 in silico. (A) The homology model of human LANCL2 is shown in Cartoon
representation with coloring according to secondary structure. Purple: alpha helix; Blue: other helix; Yellow: bridge_beta; Cyan: turn; Green: coil. (B) 2-
D structure of NSC61610. (C) Representative binding mode of the most stable docked orientation of NSC61610 with LANCL2. The LANCL2 model is
shown in ribbon mode. NSC61610 pose generated by AutoDock Vina is colored in cyan and the one generated by AutoDock is colored in orange.
Selected residues of LANCL2 (blue) are depicted by stick-and-ball models and colored by atom types. Amino acid residues surrounding NSC61610 are
labeled. (D) Representative binding modes of the docked orientation of abscisic acid (ABA) and NSC61610 with LANCL2. LANCL2 is shown in a ribbon
mode. NSC61610 (orange) and ABA (magenta) are shown in stick-and-ball model. Selected residues of LANCL2 surrounding both NSC61610 and ABA
are depicted by stick-and-ball model and labeled. The images were rendered in Visual Molecular Dynamics (VMD).
doi:10.1371/journal.pone.0034643.g001
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method to identify pairwise treatments with significant difference.
Reverse docking NSC61610 to Novel Potential Drug
Targets
The potential drug target database (PDTD) is a dual function
database that associates an informatics database to a structural
database of known and potential drug targets. PDTD is a
comprehensive, web-accessible database of drug targets, and
focuses on those drug targets with known 3D-structures. The
target proteins collected in PDTD were selected from the
literature, and from several online databases, such as DrugBank
and Therapeutic Targets Database (TTD). PDTD contains 1,207
entries covering 841 known and potential drug targets with
structures from the PDB. Drug targets of PDTD were categorized
into 15 and 13 types, respectively, according to two criteria:
therapeutic areas and biochemical criteria [22]. Target Fishing
Dock (TarFisDock) is a web-based tool for seeking potential
binding proteins for a given ligand. It applies a ligand-protein
reverse docking strategy to search out all possible binding proteins
for a small molecule from the PDTD [23]. TarFisDock was
developed on the basis of DOCK (version 4.0) program [24]. The
reverse docking procedure is as follows: 1) The NSC61610
structure file in sdf format was downloaded from PubChem (SID
109036). The NSC61610 structure file was transformed to the
standard mol2 format using the Chimera program [25]. 2)
TarFisDock docked NSC61610 into the possible binding sites of
proteins in the target list. Putative binding proteins are selected by
ranking the values of the interaction energy, which is composed of
van der Waals and electrostatic interaction terms.
Results
Virtual Screening and Result Analysis
In a previous study, we constructed the homology model of
LANCL2 according to the crystal structure of LANCL1 using
SWISS-MODEL Workspace [26]. The structure of LANCL2 is
shown in Figure 1A [27]. Two levels of assessment, ANOLEA [28]
and PROCHECK [29], both indicated the good quality of the
model [10].
To discover novel naturally occurring compounds, new drugs
and repurposed drugs that target the LANCL2 and potentially
exert insulin-sensitizing and anti-inflammatory actions, virtual
screening was applied to identify potential ligands of LANCL2.
The compound databases used for screening contain NCI
Diversity Set II, ChemBridge and ZINC natural product, existing
drug databases and FDA-approved drugs databases.
During the in silico screening process, compounds were ranked
according to their estimated free energy of binding. The best ten
docking solutions based on the energy scores were selected for
each database (Tables S2, S3, S4, and S5) using AutoDock Vina.
A lower binding free energy indicates a more stable protein-ligand
system and a higher affinity between protein and ligand. In our
integrated discovery pipeline, lead compounds in each category
are further validated by in vitro testing and pre-clinical studies using
mouse models of human diseases. NSC61610, the structure of
which is given in Figure 1B, had the lowest free energy of binding
(211.1 kcal/mol) compared to other compounds in NCI Diversity
Set II. To further verify the binding between NSC61610 and
LANCL2 in silico, we docked NSC61610 to LANCL2 using
AutoDock (version 4.2) [19]. The detailed approach is the same as
the one we applied in docking experiments of ABA [10]. The 100
resulting poses of NSC61610 were clustered with an RMSD
cluster tolerance of 2.0 A ˚. The lowest binding energy pose in the
first cluster was considered as the most favorable docking pose.
The region on the LANCL2 with the first cluster was considered as
the potential binding site for NSC61610. By comparing the amino
acid residues involved in binding sites, we found the binding sites
predicted by the two different docking programs were identical to
each other in most regions. The shared amino acid residues
included ARG102, VAL103, TYR189, THR196, ASP414,
LEU416, GLY417, ARG422, and LEU428 (Fig. 1C). Thus, the
identical region on the LANCL2 identified by the two docking
programs was considered as the potential binding site for
Figure 2. Effect of LANCL2 disruption and cAMP inhibition on PPAR c activation in RAW 264.7 macrophages. Cells were cotransfected
with a pTK.PPRE3x luciferase reporter plasmid driven by the PPRE-containing Acyl-CoA oxidase promoter with or without LANCL2 siRNA. Then, cells
were treated with vehicle (DMSO) or NSC61610 (2.5 mM), the adenylate cyclase-specific inhibitor 2959-dideoxyadenosine (10 mM). Luciferase activity
was normalized to pRL activity in the cell extracts and relative luciferase activity was calculated a ratio of the activity in the treatment wells to control
wells. Data are represented as mean 6 standard error. Points with an asterisk indicate that a treatment is significantly different from its control
(P,0.05).
doi:10.1371/journal.pone.0034643.g002
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identified a binding site for NSC61610 on LANCL2 that is similar
to the binding site for ABA (Fig. 1D) [10]. Since the binding
energy is only one of many possible criteria for identifying
potential binding sites, further experimentation was needed to
verify the binding site of NSC61610 or determine whether
NSC61610 has multiple binding sites on LANCL2.
Knockdown of LANCL2 Disrupts NSC61610-induced
PPAR c Activation
To determine PPAR c activity, pCMX.PPAR c expression
plasmid and a pTK.PPRE3x luciferase reporter plasmid driven by
the peroxisome proliferator responsive element-containing Acyl-
CoA oxidase promoter were purified using maxi kit from Qiagen
(Valencia, CA). RAW 264.7 macrophages were cultured with
DMEM (Mediatech, Manassas, VA) containing 10% fetal bovine
serum (FBS) and grown until 60–70% confluence. Cells were
cotransfected in two 25 cm2 flasks with 1.5 mg plasmid of DNA
and 0.15 mg of pRL reporter control with or without 100 pmol
LANCL2 siRNA using Lipofectamine 2000 transfection reagent
(Invitrogen) according to the manufacturer’s protocol. After 24 h,
transfected cells were seeded into white, opaque 96-well plates (BD
Biosciences) at a concentration of 25,000 cells/well. Transfected
cells were then treated in replicates with rosiglitazone (Ros 1 mM;
Cayman Chemical, Ann Arbor, MI), NSC61610 (2.5 mM) with
and without 2959-dideoxyadenosine (10 mM; Sigma) or vehicle
(DMSO) and placed in a 37uC incubator with 5% CO2. After
20 h, cells were harvested in reporter lysis reagent. Luciferase
activity, normalized to pRL activity in the cell extracts, was
determined by using the Dual-Luciferase II reporter assay system
(Promega, Madison, WI) using a Modulus 96-well luminometer
(Turner Biosystems, Sunnyvale, CA). All values were normalized
to control wells to calculate relative luciferase activity. In the same
project, we assessed whether introduction of LANCL2 siRNA
affects NSC61610-induced PPAR c activation. To measure the
effect of LANCL2 knockdown on NSC61610-induced PPAR c
activation, raw macrophages were transfected with a PPAR c
expression and dual luciferase plasmids with or without l LANCL2
siRNA, and treated with NSC61610 (2.5 mM). Our data indicate
that the addition of LANCL2 siRNA disrupted PPAR c activation
by NSC61610 (Fig. 2).
NSC61610 activates PPAR c by AC-cAMP Signaling
Pathway
To determine whether NSC61610-induced activation of PPAR
c is dependent on adenylate cyclase (AC)-cyclic adenosine
monophosphate (cAMP) signaling, raw macrophage were treated
with NSC61610 (2.5 mM) with or without 2959-dideoxyadenosine
(10 mM). NSC61610 increased PPAR c activity and addition of
the AC-specific inhibitor prevented NSC61610-induced PPAR c
activation (Fig. 2). We also examined whether the inhibitor
influenced PPAR c activity in raw macrophage with knockdown of
LANCL2. The PPAR c activity was not further reduced by
addition of AC-specific inhibitor (Fig. 2).
NSC61610 Ameliorates Disease Activity and Inflammatory
Lesions in Mice with IBD
To determine the effect of NSC61610 on colonic inflammation
we performed a dose-response study. Specifically, mice received
placebo or were treated orally with increasing concentrations of
NSC61610 (0.5, 10 and 20 mg/kg body weight) for 7 days during
a DSS challenge. After 7 days, mice treated with NSC61610 had a
significantly reduced disease activity index (DAI) compared to
Figure 3. Oral treatment with NSC61610 ameliorates experi-
mental inflammatory bowel disease. Mice were challenged with
2.5% dextran sodium sulfate in the drinking water for 7 days. Disease
activity index (DAI), a composite score reflecting clinical signs of the
disease (i.e. perianal soiling, rectal bleeding, diarrhea and piloerection),
was assessed daily. Panel A illustrates the effect of NSC61610 on disease
severity in mice with colitis. Panels B–D illustrate the effect of NSC61610
on macroscopic inflammatory lesions in the colon (B), spleen (C), and
mesenteric lymph nodes (MLN) (D). Data are represented as mean 6
standard error (n=10). In figure A, data points with asterisks are
significantly different from control and data points with two asterisks
are significantly different from those with one asterisk (P,0.05). In
figure B–D, bars with an asterisk indicate that a treatment is significantly
different from its control (P,0.05).
doi:10.1371/journal.pone.0034643.g003
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observation from Figure 3B, 3C, and 3D, NSC61610 treatment
significantly decreased inflammation caused by DSS in colon,
spleen and MLN. To more closely examine the effect of
NSC61610, colonic specimens were examined histologically for
the presence of inflammatory lesions. Our data indicate that
NSC61610 significantly reduced epithelial erosion, mucosal
thickening and leukocyte infiltration in mice with DSS colitis
(Fig. 4).
NSC61610 Modulates Colonic Gene Expression
Our previous research suggested that ABA activates PPAR c,
and PPAR c agonists have been successfully used in the treatment
of IBD [30]. Thus, we sought to determine whether NSC61610
modulates gene expression in a manner that resembled established
agonists of PPAR c such as rosiglitazone or conjugated linoleic
acid. Here, we found evidence of PPAR c-mediated effects in
colons of NSC61610-treated mice. For instance, NSC61610
increased the PPAR c gene expression in colon compared with
control mice (Fig. 5A). In addition, NSC61610 significantly
lowered expression of inflammatory mediators including monocyte
chemoattractant protein-1 (MCP-1) (Fig. 5B) and interleukin-6
(IL-6) (Fig. 5C) in colons of DSS-challenged mice.
NSC61610 Influences the Phenotype and Distribution of
Immune Cells in Mice with IBD
To determine the effect of NSC61610 on immune cell subsets,
we performed flow cytometric analysis on cells isolated from the
colon, spleen, MLN, and blood. Our analyses indicated that
NSC61610 significantly increased the percentage of Treg cells in
colon, spleen, and blood (Fig. 6). The highest concentration
NSC61610 (20 mg/kg) also significantly increased the percentages
of CD4+ IL10+ T cells in colon, spleen, MLN, and blood. In
addition, NSC61610 numerically reduced the percentage of F4/
80+CD11b+ macrophages infiltrating the colonic lamina propria
(Fig. 7).
NSC61610 Reduces Disease Activity and Inflammatory
Lesions via a PPAR c-dependent Mechanism
To investigate whether the beneficial effects of NSC61610 in
IBD required expression of PPAR c in T cells or macrophages,
wild-type (PPAR c fl/fl, Cre-) mice, macrophage-specific PPAR c
null mice (PPAR c fl/fl; lysozyme M-Cre+) and T cell-specific
PPAR c null mice (PPAR c fl/fl; CD4-Cre+) were challenged with
2.5% DSS in the drinking water for 6 days, and disease activity
was monitored daily. Macrophage-specific PPAR c null mice had
worsened disease activity throughout the challenge period. From
day 4, macrophage-specific PPAR c null mice had a significantly
higher disease activity compared with PPAR c fl/fl Cre- and
PPAR c fl/fl; CD4-Cre+ mice in both control and treatment
groups (Fig. 8A). In line with the DAI scores, both the colons and
spleens were significantly more inflamed in PPAR c fl/fl;
Lysozyme M-Cre+ mice than PPAR c fl/fl Cre- and PPAR c
fl/fl; CD4-Cre+ mice (Fig. 8B and 8C).
Based on the results of the dose response study showing
maximum anti-inflammatory efficacy at the highest dose tested, we
used an oral dose of 20 mg NSC61610/kg body weight via gastric
gavage in this study. NSC61610 treatment significantly reduced
DAI compared to untreated control mice following the DSS
challenge (Fig. 8A). To more closely examine the effect of
NSC61610 on immunopathology caused by DSS, colons, spleens
and MLNs were examined macroscopically for the presence of
Figure 4. Oral treatment with NSC61610 ameliorates inflammatory lesions in mice with inflammatory bowel disease. Mice were
challenged with 2.5% dextran sodium sulfate in the drinking water for 7 days. Representative photomicrographs from the control (A–B) and
NSC61610 treatment (C–E) groups are illustrated. Colonic specimens underwent blinded histological examination and were scored based on
epithelial erosion (F), mucosal wall thickening (G), and leukocyte infiltration (H). Data are represented as mean 6 standard error (n=10). Bars with an
asterisk indicate that a treatment is significantly different from its control (P,0.05).
doi:10.1371/journal.pone.0034643.g004
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cantly reduced macroscopic inflammatory lesions in PPAR c-
expressing and T cell-specific PPAR c null mice with DSS colitis
(Fig. 8B, 8C and 8D). However, the therapeutic effect of
NSC61610 on IBD was abrogated in spleens and MLNs of
macrophage-specific PPAR c null mice (Fig. 8C and 8D). Thus,
we posit that the anti-inflammatory efficacy of NSC61610 is
dependent on PPAR c expression in macrophages.
Discussion
LANCL2 has received some recent attention as a potential
therapeutic target due to its function related to ABA binding and
signaling [6] and the recent discovery of an alternative membrane-
based mechanism of PPAR c activation [8]. Furthermore, we
determined the LANCL2 expression in a series of mouse tissues,
which showed that beside brain and testis, LANCL2 is also
expressed in other tissues, such as thymus, spleen, colon, and PP,
which indicates the possible relationship between LANCL2 and
immune responses and suggest the broader potential of LANCL2
as a therapeutic target.
ABA has been shown to play an important role in regulating
immune and inflammatory processes [8] via PPAR c-mediated
responses in mouse models of obesity-related inflammation,
diabetes, atherosclerosis, and IBD [30,31,32,33,34]. We discov-
ered that ABA activates PPAR c and the loss of PPAR cin
immune cells impairs its ability to normalize blood glucose
concentrations and ameliorate macrophage infiltration in the
white adipose tissues of obese mice [32]. PPAR c suppresses the
expression of pro-inflammatory cytokines and chemokines by
antagonizing the activities of transcription factors, enhancing
nucleocytoplasmic shuttling of the activated p65 subunit of NF-kB,
and targeting co-repressor complexes onto inflammatory gene
promoters [8]. These molecular changes induced by PPAR c
agonists are linked to anti-inflammatory efficacy in mouse models
of systemic and mucosal inflammation [8,31,35].
At the molecular level, the mechanism underlying ABA-
mediated activation of PPAR c is independent of direct binding
to PPAR c’s LBD [8]. The inability of ABA to bind directly to the
LBD was further validated by competitive ligand-binding assays
demonstrating the inability of ABA to displace the trace for
binding to the PPAR c LBD. These results suggested existence of a
potential molecular target for ABA upstream of PPAR c. ABA was
shown to increase cAMP accumulation in insulin-secreting
pancreatic b-cell lines, splenocytes, and macrophages [34,36].
LANCL2 represents a possible membrane-associated target for
ABA involved in the initiation of the cAMP signal. In a previous
study on LANCL2 in silico, we used homology modeling
approaches to construct a three dimensional structure of LANCL2
and identified a putative ABA-binding site on the surface of
LANCL2 [10]. A series of in vitro experiments further demon-
strated that LANCL2 is a putative novel target for the discovery
and development of orally active, broad-based drugs against
inflammatory, infectious and chronic metabolic diseases. In this
study, we used LANCL2 docking studies for the large-scale, high-
throughput screening of thematic compound databases for novel
drugs for treating inflammatory, infectious and chronic diseases.
These molecular modeling studies facilitated that discovery of
numerous potential ligands of LANCL2 from NCI Diversity Set
II, ChemBridge, ZINC natural products, FDA-approved drugs
database and ABA analogs. Furthermore, in order to validate
these predictions and determine the anti-inflammatory efficacy of
the top ranked compound, denoted as NSC61610 in NCI
Diversity Set II, a series of in vitro and pre-clinical efficacy studies
using a mouse model of DSS-induced colitis were performed.
Previously, we have reported that ABA transactivates PPAR c in
vitro and suppresses systemic inflammation similar to other PPAR c
agonists. Since both ABA and NSC61610 target LANCL2,
Figure 5. Modulation of colonic gene expression by oral
treatment with NSC61610. Mice were challenged with 2.5% dextran
sodium sulfate in the drinking water for 7 days. Colonic mRNA
expression of peroxisome proliferator-activated receptor c (PPAR c) (A),
monocyte chemoattractant protein-1 (MCP-1) (B), and interleukin-6 (IL-
6) (C) were assessed by quantitative real-time RT-PCR. Data are
represented as mean 6 standard error (n=10). Bars with an asterisk
indicate that a treatment is significantly different from its control
(P,0.05).
doi:10.1371/journal.pone.0034643.g005
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results show that NSC61610 treatment activates PPAR c in raw
macrophages, thereby providing evidence of a potential signaling
relationship between LANCL2 and PPAR c and indicating that
NSC61610 might target the LANCL2-PPAR c axis in vitro.T o
investigate the importance of LANCL2 in NSC61610-mediated
activation of PPAR c, we determined whether knocking down
LANCL2 in raw macrophages by using siRNA impaired or
abrogated the effect of NSC61610 on PPAR c reporter activity.
Our findings indicate that knocking down LANCL2 significantly
Figure 6. Oral treatment with NSC61610 on the distribution of immune cell subsets in colonic lamina propria and spleen. Colonic
lamina propria lymphocytes (LPL, A, B, and E) and spleen (C and D), were immunophenotyped to identify regulatory T cells (Treg) and CD4+IL-10+ T
cell subsets through flow cytometry. Data are represented as mean 6 standard error (n=10). Bars with an asterisk indicate that a treatment is
significantly different from its control (P,0.05).
doi:10.1371/journal.pone.0034643.g006
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findings are consistent with the prediction of our previous studies
that ABA activates PPAR c reporter activity in an LANCL2-
dependent manner [8]. In addition, to determine whether
NSC61610-induced activation of PPAR c is dependent on
adenylate cyclase-cAMP signaling, we measured the NSC61610-
induced PPAR gamma activity with or without 2959-dideoxyade-
nosine, AC-specific inhibitor. AC transmits signals by converting
adenosine triphosphate to cAMP, a second messenger. The results
show addition of the AC-specific inhibitor prevented NSC61610-
induced PPAR gamma activation, which indicates NSC61610-
induced PPAR gamma activation is AC/cAMP dependent. We
also examined whether the AC-specific inhibitor influenced PPAR
c activity in cells with knockdown of LANCL2. The PPAR c
activity was not further inhibited with addition of AC-specific
inhibitor that indicates that LANCL2 is one receptor upstream of
AC-cAMP signaling pathway, which is in line with our previous
findings that LACNCL2 stimulation is followed by cAMP
accumulation [8].
Herein, we demonstrate for the first time that oral NSC61610
treatment significantly ameliorates colonic inflammation and
clinical activity in mice with experimental IBD. Consistent with
in vitro results in raw macrophages showing increased PPAR c
reporter activity, we found that NSC61610 treatment upregulated
colonic PPAR c gene expression in mice with IBD. In addition,
NSC61610 significantly decreased inflammatory mediators in the
colonic mucosa, including MCP-1 and IL-6. MCP-1 plays an
important role in the pathogenesis of colitis in relation to the
recruitment of immune cells, and the absence of this chemokine is
associated with a significant reduction in inflammation [37].
CD4+ T cells at the site of inflammation are critically dependent
on anti-apoptotic IL-6 signaling. This circle of T cell accumula-
tion, mediated by apoptosis resistance, which leads to chronic
inflammation, can be blocked by anti-IL-6 receptor antibodies
[38]. In combination with transforming growth factor-b, IL-6 is
also involved in differentiation of naı ¨ve CD4+ T cells into a pro-
inflammatory T helper (Th) 17 phenotype that has been associated
with autoimmunity [39].
Figure 7. Oral treatment with NSC61610 on the distribution of macrophages in colonic lamina propria. Colonic lamina propria
lymphocytes (LPL) were immunophenotyped to identify F4/80+CD11b+ macrophage subsets through flow cytometry. Data are represented as mean
6 standard error (n=10). Bars with an asterisk indicate that a treatment is significantly different from its control (P,0.05).
doi:10.1371/journal.pone.0034643.g007
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significantly increased the percentages of Treg cells in the colon,
spleen, and blood of mice. Tregs are important for the
maintenance of intestinal self-tolerance and suppression of
inflammation. Therapies that increase Treg numbers and function
are under intense investigation and may prove to be promising
treatments for patients with IBD [40,41]. In addition, treatment
with NSC61610 at the highest concentration also significantly
increased the percentages of CD4+IL10+ T cells in colon, spleen,
MLN, and blood. IL-10 is a regulatory cytokine that inhibits both
antigen presentation and subsequent pro-inflammatory cytokine
release, and it is proposed as a potent anti-inflammatory biological
Figure 8. Effect of tissue-specific PPAR c deletion and oral NSC61610 treatment in experimental inflammatory bowel disease. Mice
were challenged with 2.5% dextran sodium sulfate in the drinking water. Panel A illustrates the effect of oral NSC61610 treatment on disease severity.
Means within time points with different letterssuperscripts are significant different (P,0.05). Panels B–D illustrate the effect of oral NSC61610 on
macroscopic lesions in the colon (B), spleen (C), and mesenteric lymph nodes (MLN) (D). Data are represented as mean 6 standard error (n=10). Bars
with an asterisk indicate that a treatment is significantly different from its control (P,0.05).
doi:10.1371/journal.pone.0034643.g008
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the percentage of infiltrating F4/80+CD11b+ macrophages in the
colonic lamina propria, a possible source of inflammatory
mediators. Our previous research indicated that ABA ameliorates
experimental IBD by suppressing immune cell infiltration [31,35],
which meshes with the immunosuppressive responses seen with
NSC61610. This commonality may indicate that ABA and
NSC61610 do indeed share similar anti-inflammatory mecha-
nisms that are possibly initiated via LANCL2 binding. In previous
study on ABA, we found T cell PPAR c is a crucial mediator of
ABA’s anti-inflammatory responses. The absence of PPAR c in T
cells essentially abolished the ability of ABA to decrease
experimental IBD, including the anti-inflammatory action of
ABA in the colon. T cell PPAR c was required for the regulation
of Treg cell number in the mucosal inductive (MLNs) and effector
(colonic lamina propria) sites [30]. To investigate the cell
specificity and molecular targets underlying the anti-inflammatory
mechanism of NSC61610 in vivo, we tested whether the beneficial
effect of NSC61610 in IBD required expression of PPAR c in T
cells or macrophages. Since the beneficial effect of NSC61610
treatment on IBD was abrogated in macrophage-specific PPAR c
null mice, we posit that the anti-inflammatory efficacy of
NSC61610 is dependent on PPAR c expression in macrophages.
Although the anti-inflammatory mechanisms of ABA and
NSC61610 are involve LANCL2, their differences in cell
specificity indicate that activation of LANCL2 possibly can trigger
multiple signal pathways in different cells which would finally
promote PPAR c expression and exert anti-inflammatory efficacy.
Based on this finding, synergistic effect of ABA and NSC61610
will be tested in our future studies.
In an attempt to identify additional targets to shed new light on
potential alternative mechanisms of action for NSC61610 we used
TarFisDock to analyze the reverse docking results of this
compound. Putative targets were selected by ranking the values
of the interaction energy, which consist of van der Waals and
electrostatic interaction terms. The top 10 reverse docking results
of NSC61610 are shown in Table S6. Of note, we show novel data
indicating that NSC61610 may decrease inflammation by
alternatively targeting the leukotriene A4 hydrolase, which is an
enzyme linked to the production of inflammatory lipid mediators
such as leukotrienes, suggesting a possible role of NSC61610 in
modulating the synthesis of lipid mediators such as prostaglandins
and leukotrienes that worsen the pathogenesis of IBD. It is obvious
that the docking energy scores obtained in TarFisDock are more
negative than those in AutoDock and AutoDock Vina, which is
generated by the differences between scoring functions. TarFis-
Dock was developed on the basis of the DOCK (version 4.0)
program with a force-field-based scoring function, while Auto-
Dock and AutoDock Vina use an empirical scoring function.
Different scoring functions have been compared and assessed in
previous studies [44]. In terms of the TarFisDock energy score,
this value represented strength of ligand association where a more
negative value translated to a stronger predicted protein-ligand
complex.
In conclusion, this study employed an integrated drug discovery
pipeline consisting of molecular modeling approaches followed by
experimental validation. We performed large-scale screening of
compound libraries based on predicted binding to an LANCL2
binding site and identified novel putative compounds for the
treatment of inflammatory diseases. NSC61610, the top ranked
lead compound based on binding free energy, significantly
ameliorated experimental IBD in mice in a LANCL2- and PPAR
c-dependent manner. These results confirm that LANCL2 is a
novel therapeutic target for inflammatory diseases and NSC61610
is a potential new drug.
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